Azithromycin is not effective in the treatment of old world cutaneous leishmaniasis [11]

European Journal of Dermatology

Volumn 16, Issue 6, 2006, Pages 701-702

  Momeni, Ali Z ^a   Shafiei, Ali ^a   Emamjoeh, Morteza ^a   Aminjavaheri, Malihalsadat ^a   Momeni, Amir ^a  

^a Aminjavaheri Medical Lab   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IN VITRO STUDY; IRAN; LETTER; MULTIPLE CYCLE TREATMENT; SKIN LEISHMANIASIS; TREATMENT FAILURE; TREATMENT RESPONSE;

ANIMALS; AZITHROMYCIN; FEMALE; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MALE; TREATMENT OUTCOME;

EID: 33846786958     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2006.0018     Document Type: Letter

References (6)

1. Prata A, Silva-Vergara ML, Costa L, Rocha A, et al. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical 2003; 36(1): 65-9.
2. Silva-Vergara ML, Silva LA, Maneira F, Silva A. Azithromycin in the treatment of mucosal leishmaniasis. Rev Ins Med Trp S Paulo 2004; 16: 175-7.
3. Weinrauch L, el-On J. current therapy of cutaneous leishmaniasis. Int J Dermatol 1987; 9: 564-70.
4. Krolewiecki AJ, Scott P, Abrham D. The anti-leishmania activity of azithromycin an in-vitro model. Revista da Sociedade Brasileria de Medicine Tropical 1999; 32: 137.
5. Shazad B, Abbaszadeh B, Khamesipour A. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol 2005; 15(2): 85-7
6. Momeni AZ, Aminjavaheri M. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol. Eur J Dermatol 2003; 13(1): 40-3.